Medigene’s iM-TCR Technology Receives Japanaese Patent

Medigene Expands Patent Portfolio in Japan for iM-TCR Technology Enhancing TCR-T Safety and Efficacy

Overview

Medigene AG has recently received a patent from the Japan Patent Office for its inducible Medigene T cell receptor (iM-TCR), a mechanism designed to regulate the efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies.

Medigene CEO on Efficacy and Safety 

• Selwyn Ho, CEO at Medigene, expressed satisfaction with the patent grant, noting its importance in expanding the company's intellectual property portfolio. 
• He emphasized the potential of the iM-TCR to provide tailored efficacy and safety for individual patients by controlling TCR activity post-administration. 
• Ho also highlighted the iM-TCR as an example of Medigene's End-to-End Platform, which includes various proprietary armoring and enhancement technologies. 
• By combining the iM-TCR with their optimal 3S (sensitive, specific, and safe) TCRs, Medigene aims to deliver innovative solutions that optimize the safety and efficacy of TCR-T therapies.

TCR-T Against Cancer

• TCR-T therapies have demonstrated effectiveness in killing tumor cells, but excessive T cell activation can lead to issues such as premature exhaustion, cell death, and unwanted inflammatory responses. 
• The iM-TCR technology addresses these concerns by modulating TCR surface expression, enabling precise adjustment of activity against tumor cells while reducing inflammatory responses in the body. 
• This feature is particularly promising for sensitive organs affected by sustained inflammatory reactions caused by T cells, such as those seen in brain or liver cancer.